Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Merck
QuintilesIMS
McKesson
UBS
Cerilliant
Harvard Business School
US Army

Generated: July 16, 2018

DrugPatentWatch Database Preview

Mifepristone - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for mifepristone and what is the scope of mifepristone freedom to operate?

Mifepristone
is the generic ingredient in two branded drugs marketed by Corcept Therap and Danco Labs Llc, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mifepristone has two patent family members in two countries.

There are six drug master file entries for mifepristone. One supplier is listed for this compound.
Summary for mifepristone
Pharmacology for mifepristone
Synonyms for mifepristone
(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one
(10S,11S,14S,15S,17R)-17-[4-(DIMETHYLAMINO)PHENYL]-14-HYDROXY-15-METHYL-14-(PROP-1-YN-1-YL)TETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-1,6-DIEN-5-ONE
(11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(non-labelled)Mifepristone-d3
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
11|A-(4-Dimethyl-amino)-phenyl-17|A-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
11|A-[4(dimethylamino)phenyl]-17|A-hydroxy-17|A-(1-propynyl)-estra-4,9-diene-3-one
11b-(p-(dimethylamino)phenyl)-17b-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
1nhz
29523-EP2272827A1
29523-EP2275420A1
29523-EP2295055A2
29523-EP2295416A2
29523-EP2298748A2
29523-EP2298764A1
29523-EP2298765A1
29523-EP2305642A2
29523-EP2308880A1
29523-EP2311453A1
29523-EP2311808A1
29523-EP2311829A1
29523-EP2311842A2
2w8y
320T6RNW1F
371M653
75603-EP2269977A2
75603-EP2308880A1
83203-42-3
84371-65-3
A840767
AB2000695
ABP000437
AC1L1IOO
ACT02598
AJ-45776
AK128404
AKOS015895416
Ambap84371-65-3
AN-10301
ANW-41472
AOB6893
API0003390
ARONIS27015
AS-13938
BDBM18627
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C07652
C29H35NO2
CAS-84371-65-3
CCG-101164
CCRIS 9332
CHEBI:50692
CHEMBL1276308
CI-1073
Corlux
CPD000058481
CS-1435
CTK8B2959
D00585
DB00834
DSSTox_CID_3322
DSSTox_GSID_23322
DSSTox_RID_76976
DTXSID5023322
Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-
Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)-
Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-
EU-0100801
FT-0082666
FT-0602519
GTPL2805
HMS1568L20
HMS2052L05
HMS2090L22
HMS2095L20
HMS2230P21
HMS3262B03
HMS3649J08
HSCI1_000369
HSDB 6841
HY-13683
Korlym
Korlym (TN)
Lopac0_000801
LP00801
LS-64723
M 8046
MFCD00867226
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (JAN/USAN/INN)
Mifepristone (Mifeprex)
Mifepristone [USAN:INN:BAN]
Mifepristone 1.0 mg/ml in Acetonitrile
Mifepristone, >=98%
Mifepristone, United States Pharmacopeia (USP) Reference Standard
Mifepristone(Mifeprex)
Mifepristone(Mifeprex)/
Mifepristonum
Mifepristonum [Latin]
mifestone
MLS000069785
MLS001074115
MLS001424271
MolPort-003-849-222
NC00414
NCGC00025179-05
NCGC00025179-06
NCGC00025179-07
NCGC00025179-08
NCGC00025179-09
NCGC00025179-12
NCGC00025179-13
NCGC00179632-01
NCGC00255152-01
NCGC00261486-01
Opera_ID_562
Pictovir
Pictovir (TM)
PL008707
Prestwick_570
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Q-201405
R 38486
R-38486
R38486
RL05189
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex
RU486
RU486 (tetramethyl-rhodamine conjugated)
s2606
SC-16222
SCHEMBL16087
SMR000058481
SPBio_002457
Spectrum5_002045
SR-01000076011
SR-01000076011-5
SR-01000076011-9
TL8005515
Tox21_110952
Tox21_110952_1
Tox21_301841
Tox21_500801
TR-026092
UNII-320T6RNW1F
VGX-410
VGX-410C
VKHAHZOOUSRJNA-GCNJZUOMSA-N
VX-410
W-5163
ZINC3831128
ZK-98296
ZK98296

US Patents and Regulatory Information for mifepristone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Corcept Therap KORLYM mifepristone TABLET;ORAL 202107-001 Feb 17, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for mifepristone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Danco Labs Llc MIFEPREX mifepristone TABLET;ORAL 020687-001 Sep 28, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for mifepristone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,598,149 Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Argus Health
Daiichi Sankyo
McKesson
Cipla
Accenture
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.